Clinical Trial Update: A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO [Phase 2]

View source ↗

Summary

A Phase 2 dose-masked trial evaluating intravitreal Eye103 in participants with neovascular age-related macular degeneration or macular edema following branch r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYE103

Snippet

Sponsor: EyeBiotech Ltd. | Conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) | Phase 2 | Status: RECRUITING